Ubrogepant
目录号: A21670
CGRP 拮抗剂
Ubrogepant (MK-1602) 是一种新型口服 钙化基因相关肽受体(CGRP)拮抗剂,正在开发中,用于急性治疗偏头痛。
| Discription | Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine. |
|---|
| 目录号 | A21670 |
|---|---|
| 分子式 | C29H26F3N5O3 |
| 分子量 | 549.54 |
| CAS号 | 1374248-77-7 |
| SMILES | O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O |
| 其他名称 | MK-1602, MK1602, MK 1602 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2